Komor and colleagues described cytosine base editors that pair a CRISPR targeting system with a deaminase to convert one DNA base into another at a selected site.
Because the approach does not rely on a conventional double-strand break, it opened a different design space for correcting some point mutations. Its editing window, bystander changes, delivery and cell context remain important constraints.
Base editing is a research technology with therapeutic promise, not a universal or risk-free repair method. Safety, off-target assessment and long-term effects must be evaluated for each application.
STKEY note: summary based on the original proof-of-concept paper.